
Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target
Lexicon Pharmaceuticals (LXRX) Analyst Ratings
Bulls say
Lexicon Pharmaceuticals Inc. has demonstrated a positive outlook primarily due to favorable topline results from the Phase 2b PROGRESS clinical trial for its drug candidate LX9211, which effectively treated diabetic peripheral neuropathic pain. The successful identification of an optimal 10 mg dose positions the company for future Phase 3 trials and signifies potential for enhanced market penetration in critical therapeutic areas such as heart failure and cardiometabolic disorders. Additionally, the strong partnership interest in pilavapadin underscores the significant addressable market, further contributing to an optimistic growth trajectory for the company.
Bears say
The analysis of Lexicon Pharmaceuticals Inc. indicates a negative outlook primarily due to disappointing results from their RELIEF DPN-1 trial, where the 20 mg dose failed to achieve statistical significance compared to placebo, raising concerns about its efficacy. Additionally, there are significant risks related to potential failed or inconclusive clinical trials and the company's ability to secure adequate funding for ongoing drug development, which could hinder future progress. Tolerability issues at higher doses and a higher dropout rate further complicate the outlook, potentially impacting investor confidence and future valuations.
This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Lexicon Pharmaceuticals (LXRX) Analyst Forecast & Price Prediction
Start investing in Lexicon Pharmaceuticals (LXRX)
Order type
Buy in
Order amount
Est. shares
0 shares